Buy the Milestone, Ignore the Quarterly Noise: Protalix (PLX) as a Milestone-Driven Swing Trade
Protalix reported a near-term revenue disappointment that spooked traders, but the company just unlocked a $25 million regulatory milestone from Chiesi after EU approval of an every-4-week dosing regimen for Elfabrio. With a market cap around $164M, EV ~$157M, an oversold technical setup and modest days-to-cover for shorts, this is a tactical long …